Dec 31,2021

Enhancing neural markers of attention in children with ADHD using a digital therapeutic

This study aims to examine intervention-related changes in a neural marker of attentional control (MFT) in a cohort of children meeting diagnostic criteria for ADHD, and examine the AKL-T01 improvements in a broad, heterogenous population of children with ADHD. Research enrolled 28 children with a confirmed ADHD diagnosis (based on DSM-5 criteria), between March 2019 to February 2020. Teh findings showed the relationships between the neural and behavioral cognitive improvements, demonstrating that those children who showed the largest intervention-related neural gains were also those that improved the most on the behavioral tasks indexing attention.

CLINICAL STUDY

#pdt

View Analyst & Ambassador Comments
Go to original news
Jan 13,2021

Novartis trial shows no benefits from Pear's schizophrenia app as CEO cites trial irregularities

Novartis has published results from a clinical trial of Pear Therapeutics' new digital therapeutic for schizophrenia, and the results don't paint a rosy picture. The single-blinded 112-person trial found no difference between the Pear app and a placebo app in any outcome measure, including the primary outcome measure of reducing schizophrenia symptoms. However, the trial did further establish the app's safety, as very few significant adverse effects were reported.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 24,2021

AppliedVR Completes Pivotal Trial Finding Virtual Reality Is a Holistic Treatment for Chronic Pain

AppliedVR, a pioneer advancing the next generation of digital medicine, today announced results from its pivotal randomized controlled trial (RCT), evaluating virtual reality (VR) therapy for treating chronic pain at home. The study, which was published in Journal of Medical Internet Research (JMIR), found that AppliedVR’s EaseVRx device produced “clinically meaningful” improvement in multiple pain outcomes, and had high participant satisfaction and engagement.

CLINICAL STUDY

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Feb 24,2021

Study: Pear’s reSET-O cost-effective in treating opioid-use disorder

A new analysis suggests Pear Therapeutics' FDA-cleared prescription digital therapeutic (PDT) reSET-O helps improve outcomes in patients recovering from opioid-use disorder, while lowering the cost associated with conventional treatment. The findings, published in the journal Postgraduate Medicine, showed that reSET-O plus treatment-as-usual (TAU) decreased total healthcare costs and led to higher post-treatment quality-adjusted life year (QALY) gains.

CLINICAL STUDY

#mobile app

#pdt

View Analyst & Ambassador Comments
Go to original news
Mar 03,2021

Virta Health’s Reversal Treatment Prevents Progression to Type 2 Diabetes in 97% of Prediabetes Patients, New Research Shows

Today Virta Health, the type 2 diabetes reversal leader, announced the publication of new peer-reviewed research in Nutrients. In this publication, Virta reports best-in-class outcomes in diabetes prevention, with only 3% of trial participants progressing to type 2 diabetes (T2D) and over half achieving prediabetes reversal during the first two years. Further, the trial saw strong retention, with 75% of patients retained at the two-year mark.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Mar 24,2021

Mental health chatbot Woebot could be adapted to tackle substance use

A recent study published in the Journal of Medical Internet Research (JMIR) shows initial support for a new version of Woebot – a text-based chatbot app designed to address mental health issues – that is designed to reduce substance use and other measures tied to substance use disorder (SUD). Conducted by researchers from Stanford University School of Medicine and Woebot Health, the investigation found that 101 participants in the eight-week program reported reduced cravings and increased confidence in their ability to resist urges – among other encouraging outcomes.

CLINICAL STUDY

#mobile app

#cbt

#chatbot

View Analyst & Ambassador Comments
Go to original news
Apr 28,2021

82 Percent of Employees with Panic Attacks Find Relief With Digital Therapeutic

Freespira, Inc., the maker of the first FDA-cleared digital therapeutic to significantly reduce or eliminate symptoms of panic attacks, panic disorder (PD) and post-traumatic stress disorder (PTSD) in only 28 days, today announced that the Journal of Mental Health and Clinical Psychology published data demonstrating that PD severity can be significantly reduced with its first-of-its-kind treatment. Crossover Health conducted the study with eligible employees at its Midtown, New York City health center.

CLINICAL STUDY

#telehealth

#coaching

View Analyst & Ambassador Comments
Go to original news
Jan 21,2022

Feasibility and acceptability of virtual reality for cancer pain in people receiving palliative care: a randomised cross-over study

Pain management in palliative care remains inadequate; the development of innovative therapeutic options is needed. The objective of the stduy is to determine the feasibility and preliminary effectiveness for larger randomised controlled trials of 3D head-mounted (HMD) virtual reality (VR) for managing cancer pain (CP) in adults.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 11,2022

Helping Cancer Patients Avoid Excessive Radiation

A Case Western Reserve University-led team of scientists has used Artificial Intelligence (AI) to identify which patients with certain head and neck cancers would benefit from reducing the intensity of treatments such as radiation therapy and chemotherapy. The researchers used AI tools similar to those they developed over the last decade at the Center for Computational Imaging and Personal Diagnostics (CCIPD) at Case Western Reserve.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 25,2022

The First AI Breast Cancer Sleuth that Shows its Work

Computer engineers and radiologists at Duke University have developed an artificial intelligence (AI) platform to analyze potentially cancerous lesions in mammography scans to determine if a patient should receive an invasive biopsy. But unlike its many predecessors, this algorithm is interpretable, meaning it shows physicians exactly how it came to its conclusions.

CLINICAL STUDY

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY